国泰基金经理“跳槽”罗欣药业做董秘!金融民工转型去哪?

Core Viewpoint - The transition of Jiang Ying from a fund manager at Guotai Fund to the Secretary of the Board at Luoxin Pharmaceutical reflects a growing trend of fund managers diversifying their career paths beyond traditional asset management roles [2][5][11]. Group 1: Jiang Ying's Background and Transition - Jiang Ying, born in October 1987, holds dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [5][11]. - She has over four years of experience as a fund manager at Guotai Fund, managing several funds including Guotai Science and Technology Innovation Board Two-Year Open and Guotai Small and Medium Growth [5][6]. - Jiang's management of funds resulted in varying returns, with Guotai Science and Technology Innovation Board Two-Year Open and Guotai Small and Medium Growth showing returns of approximately -12.48% and -34.28% respectively [6][8]. Group 2: Luoxin Pharmaceutical's Performance - Luoxin Pharmaceutical reported a revenue of 1.077 billion yuan in the first half of 2025, a decrease of 14.45% compared to the same period in 2024, while net profit attributable to shareholders increased by 119.95% to 17.695 million yuan [8][10]. - The company's stock price closed at 5.03 yuan per share on October 15, 2024, reflecting a significant decline of over 81% from its peak of 27.94 yuan per share since its listing [8][10]. Group 3: Industry Trends and Implications - The trend of fund managers transitioning to roles in listed companies is becoming more common, with at least four other fund managers making similar moves to become board secretaries [15]. - The number of fund managers has increased from 3,280 in 2022 to 4,072 by October 15, 2025, indicating a growing pool of talent in the industry [11][12]. - The shift in career paths among fund managers is influenced by various factors, including changes in industry dynamics, compensation structures, and the desire for diversified career opportunities [18].

LuoxinPharmaceutical-国泰基金经理“跳槽”罗欣药业做董秘!金融民工转型去哪? - Reportify